BIOMD202 - L5 Pharmacodynamics and Dose-Response Relationships

Dose Response in Pharmacodynamics

Introduction to Dose Response

  • Overview of pharmacodynamics in relation to dose response.

  • Reiteration of concepts covered previously (by Sunoli).

  • Exploration of drug response changes as dose is titrated.

  • Discussion topics to follow:
      - Definition of dose response relationship.
      - Influence of potency, affinity, and efficacy on drug effects.
      - Concepts of competitive antagonism, partial agonists, inverse agonists.
      - Onset, duration, and termination of drug response.
      - Desensitization and tolerance in pharmacodynamic responses.
      - Connection between pharmacokinetics (PK) and pharmacodynamics (PD).

Definitions and Key Concepts

  • Dose Response Relationship: The correlation between the drug dose and its physiological response, characterized by how varying doses yield different effects.
      - Maximum response (Emax): The greatest effect a drug can produce.
      - EC50: Concentration that produces 50% of the maximum response.
      - Example: Drug concentration plotted against effect generally reveals a sigmoidal (S-shaped) curve when log-transformed.

  • Affinity: Refers to the tendency of a drug to bind to a receptor.
      - Example: Low-affinity drugs require higher concentrations to achieve binding versus high-affinity drugs, which saturate receptors at lower concentrations.

  • Efficacy: The ability of a drug to activate a receptor, leading to a physiological response.
      - Standard antagonists do not activate receptors but block them.

  • Potency: Refers to the amount of drug needed to produce a given effect; often assessed by EC50 values.
      - Example: Variations in EC30 values among drugs exhibiting different potencies.

  • Therapeutic Index: The ratio of the LD50 (lethal dose for 50% of the population) to the ED50 (effective dose for 50% of the population).
      - Example: A high therapeutic index indicates a larger margin of safety.

Types of Drug Responses

  • Graded Response: Continuous increase in response with increasing drug concentration until a maximum response is observed.
      - Curve often exhibits a sigmoidal shape when plotted logarithmically.
      - EC50 can be derived from analyzing the slope of the curve.

  • Quantal Response: An all-or-nothing response, typically measured through a frequency distribution.
      - Example: Dose-response experiment on a population leading to a bell-shaped cumulative curve.

Competitive Antagonism

  • Competitive Antagonists: Compete with agonists for binding to the same receptor site.
      - Efficacy can be outcompeted by increasing the concentration of the agonist.
      - Graphical representation: Rightward shift of dose-response curve with increasing antagonist concentrations.

Irreversible Competitive Antagonism

  • When an antagonist forms a covalent bond with the receptor, preventing agonist binding.
      - Results in reduced maximum response.
      - Example drugs: Aspirin (COX inhibitors) and some cancer therapies like ibrutinib.

Partial Agonism

  • Partial Agonists: Activate receptors but produce a submaximal response even when fully bound.
      - Can act as competitive antagonists relative to full agonists.
      - Example: Buprenorphine's role as an opioid substitute that mitigates overdose risk.

Inverse Agonists

  • Activate receptors but reduce any existing basal (constitutive) activity.
      - Provides negative efficacy, lowering overall receptor activity.
      - Distinction from neutral antagonists, which do not affect receptor activity.

Onset of Action and Duration of Response

  • Onset of Action: Time from drug administration to observable effect.
      - Ligand-gated ion channels: Fast response mediated by ion influx.
      - Example: Nicotinic acetylcholine receptors at neuromuscular junctions.

  • Duration of Action: Influenced by receptor kinetics and turnover rates, alongside the pharmacokinetics of the drug.
      - Example: Prolonged effects from slow-disassociating drugs such as haloperidol.

Desensitization and Tolerance

  • Desensitization: Reduced efficacy of a drug following continuous administration.

  • Tolerance: Gradual decrease in drug response over an extended period, requiring dosage adjustments.
      - Mechanisms include receptor internalization, altered receptor functioning, or metabolic degradation of the drug.

  • Receptor Internalization: Involves phosphorylation and binding of arrestin, leading to endocytosis of receptors, affecting the availability of drug targets on the cell surface.

Linking Pharmacokinetics and Pharmacodynamics

  • Drug absorption, metabolism, and interaction affect the drug's concentration at target sites.

  • Variability in drug responses due to pharmacogenomic differences and individual patient factors.
      - Example: Warfarin and delayed effects related to the natural half-lives of clotting factors.

  • Increased understanding of PK/PD relationships can aid in optimizing therapeutic regimens and minimizing adverse effects.

Conclusion

  • Understanding the intricacies of dose response relationships is vital for effective pharmacotherapy.

  • Future studies may delve deeper into PKPD relationships and their clinical significance in drug administration.

  • The ongoing exploration of the mechanisms behind desensitization, tolerance, and receptor dynamics promises enhanced patient care and drug design strategies.